<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10206300</article-id><article-id pub-id-type="pmc">2362801</article-id><article-id pub-id-type="pii">6690291</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6990291</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Forsyth</surname><given-names>P A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">4</xref><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Wong</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Laing</surname><given-names>T D</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rewcastle</surname><given-names>N B</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>D G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">4</xref><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Muzik</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff3">4</xref><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Leco</surname><given-names>K J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref rid="note1" ref-type="fn"/></contrib><contrib contrib-type="author"><name><surname>Johnston</surname><given-names>R N</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Brasher</surname><given-names>P M A</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Sutherland</surname><given-names>G</given-names></name></contrib><contrib contrib-type="author"><name><surname>Edwards</surname><given-names>D R</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><aff id="aff1">Departments of Clinical Neurosciences and Medicine, Epidemiology and Preventive Oncology, Tom Baker Cancer Centre, 1331 29 St NW, Calgary, Alberta, T2N 4N2, Canada</aff><aff id="aff3">Departments of Medical Biochemistry, Clinical Neurosciences, Community Health Sciences, The University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada</aff><aff id="aff6">Departments of Pathology and Clinical Neurosciences, Foothills Hospital, Calgary, Alberta, T2N 4N1, Canada</aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>Tom Baker Cancer Centre, 1331 29 St NW, Calgary, Alberta, Canada T2N 4N2</corresp><fn fn-type="present-address" id="note1"><p>Present address: Ontario Cancer Institute, Princess Margaret Hospital, 620 University Ave, Toronto Ontario, Canada M5G 2L7</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>1999</year></pub-date><volume>79</volume><issue>11-12</issue><fpage>1828</fpage><lpage>1835</lpage><history><date date-type="received"><day>26</day><month>08</month><year>1998</year></date><date date-type="accepted"><day>11</day><month>09</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Matrix metalloproteinases (MMPs) have been implicated as important factors in gliomas since they may both facilitate invasion into the surrounding brain and participate in neovascularization. We have tested the hypothesis that deregulated expression of gelatinase-A or B, or an activator of gelatinase-A, MT1-MMP, may contribute directly to human gliomas by quantifying the expression of these MMPs in 46 brain tumour specimens and seven control tissues. Quantitative RT-PCR and gelatin zymography showed that gelatinase-A in glioma specimens was higher than in normal tissue; these were significantly elevated in low grade gliomas and remained elevated in GBMs. Gelatinase-B transcript and activity levels were also higher than in normal brain and more strongly correlated with tumour grade. We did not see a close relationship between the levels of expression of MT1-MMP mRNA and amounts of activated gelatinase-A. In situ hybridization localized gelatinase-A and MT1-MMP transcripts to normal neuronal and glia, malignant glioma cells and blood vessels. In contrast, gelatinase-B showed a more restricted pattern of expression; it was strongly expressed in blood vessels at proliferating margins, as well as tumour cells in some cases. These data suggest that gelatinase-A, -B and MT1-MMP are important in the pathophysiology of human gliomas. The primary role of gelatinase-B may lie in remodelling associated with neovascularization, whereas gelatinase-A and MT1-MMP may be involved in both glial invasion and angiogenesis. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>gliomas</kwd><kwd>gelatinase-A</kwd><kwd>gelatinase-B</kwd><kwd>MT1-MMP</kwd><kwd>in situ hybridization</kwd></kwd-group></article-meta></front></article>
